IQVIA provides biopharmaceutical development services and commercial outsourcing services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through two segments, Product Development and Integrated Healthcare Services. The company was founded in 1982 and is based in Durham, North Carolina.
IQV Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Iqvia Holdings Inc. To summarize, we found that Iqvia Holdings Inc ranked in the 34th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Iqvia Holdings Inc ended up being:
The company's compound free cash flow growth rate over the past 5.45 years comes in at 0.21%; that's greater than 60.17% of US stocks we're applying DCF forecasting to.
Relative to other stocks in its sector (Healthcare), Iqvia Holdings Inc has a reliance on debt greater than 67.67% of them.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as IQV, try MD, QDEL, GSK, HZNP, and OSMT.
IQVIA™ (NYSE: IQV) today introduced OCE Optimizer, an innovative solution that empowers life sciences companies to plan and refine marketing engagements with healthcare providers (HCPs) on demand. OCE Optimizer extends IQVIA’s Orchestrated Customer Engagement solution by intelligently allocating commercial resources and interaction channels for more effective connections.
IQVIA™ (NYSE: IQV) announced a new Human Data Science Research Collaborative initiative that is waiving licensing and access fees for approved academic researchers around the world to use two IQVIA data technology platforms and analytics from multiple countries to accelerate research addressing challenges and opportunities for health systems in the COVID-19 era.